Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jersey Mike's Subs Inc. Class A Common Stock (JMKE) vs Johnson & Johnson (JNJ) Price & Performance

Jersey Mike's Subs Inc. Class A Common StockTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Jersey Mike's Subs Inc. Class A Common Stock vs Johnson & Johnson — how do they compare? Jersey Mike's Subs Inc. Class A Common Stock trades at $16.95 (market cap $5.57B), while Johnson & Johnson trades at $258.62 (market cap $599.12B). The key difference: Johnson & Johnson is far larger — about 107.6× Jersey Mike's Subs Inc. Class A Common Stock's market cap, and Johnson & Johnson pays a 2.16% dividend while Jersey Mike's Subs Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jersey Mike's Subs Inc. Class A Common Stock for 0 Days and Johnson & Johnson for 129 Days on average.

JMKEJNJ
Market Cap
$5.57B$599.12B
Volume
1,926,45016,640,951
Sector
Consumer CyclicalHealth
52-Week High
$24.47$278.43
52-Week Low
$16.09$186.00
Typical Hold Time
0 Days129 Days
Enterprise Value
$7.44B$627.40B
Dividend Yield
—2.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jersey Mike's Subs Inc. Class A Common Stock

No Aura AI signal available yet.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $248.61, down 5.73% in the last session, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with $2.59 EPS versus $2.52 expected, continuing a trend of three consecutive quarterly beats. JNJ maintains robust profitability with 67.91% gross margins and 21.48% net income margins, supported by $94.19B in 2025 revenue and $26.80B net income.

Analyst consensus remains positive with 52.5% buy ratings and a $282.53 price target, representing 13.6% upside potential. Key risks include patent cliffs affecting pharmaceutical revenue and increasing debt-to-asset ratio reaching 24.06% in 2025. The company's diversified healthcare portfolio and strong dividend history provide stability, while new drug launches like Icotyde offer growth catalysts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JMKE
100% Buy0% Sell
Avg holding period · 0 Days
JNJ
84% Buy16% Sell
Avg holding period · 129 Days

Top news

Latest headlines on both assets

About Jersey Mike's Subs Inc. Class A Common Stock

Jersey Mike's Subs Inc. operates and franchises fast-casual submarine sandwich restaurants, with locations in US and Canada and franchise agreements extending to UK and Ireland.

Read more on JMKE →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ →